Key Takeaways:
- Bristol Myers Squibb's (BMY, Financial) combination treatment Opdivo and Yervoy has secured FDA approval for metastatic hepatocellular carcinoma.
- Analysts see a potential 16.56% upside in the stock, with price targets ranging between $33.10 and $70.00.
- Current analyst consensus rates the stock as "Hold" with a GF Value indicating a potential 24.24% upside.
Bristol Myers Squibb (BMY) has achieved a significant milestone with U.S. FDA approval for the Opdivo and Yervoy combination as a therapy for metastatic hepatocellular carcinoma (HCC). The approval comes in light of successful late-stage trials, highlighting the treatment's ability to improve overall survival rates compared to existing options.
Wall Street Analyst Insights
According to projections from 21 analysts, the average 12-month price target for Bristol-Myers Squibb Co (BMY, Financial) stands at $59.11. These estimates range from a high of $70.00 to a low of $33.10, indicating a potential upside of 16.56% from the current trading price of $50.71. Investors can explore more detailed estimates by visiting the Bristol-Myers Squibb Co (BMY) Forecast page.
Brokerage Recommendations
The consensus from 27 brokerage firms positions Bristol-Myers Squibb Co's (BMY, Financial) average recommendation at 2.7, classifying the stock as a "Hold". The recommendation scale extends from 1 (Strong Buy) to 5 (Sell), providing a clear snapshot of the firm's standing in the market.
Assessing GF Value
According to GuruFocus GF Value estimates, Bristol-Myers Squibb Co (BMY, Financial) could reach a valuation of $63.00 within the next year. This suggests a promising upside potential of 24.24% from its current price of $50.71. The GF Value reflects the stock's fair trading price, based on historical trading multiples, historical growth patterns, and future business performance projections. For a more comprehensive analysis, consider visiting the Bristol-Myers Squibb Co (BMY) Summary page.
